Datelliptium chloride

For research use only. Not for therapeutic Use.

  • CAT Number: M007298
  • CAS Number: 105118-14-7
  • Molecular Formula: C23H28ClN3O
  • Molecular Weight: 397.94
  • Purity: ≥95%
Inquiry Now

Datelliptium chloride is a DNA-intercalating agent derived from ellipticine, with anti-tumor activities.
Datelliptium (100 μM) shows significantly cytotoxic effects after 2 hr of treatment in suspension and primary cultures of rat hepatocytes. Datelliptium mobilizes glycogen in both rat systems in vitro concentration dependently. The half-maximal effect is 14.3 μM in isolated hepatocytes, whereas in cultured rat hepatocytes it is 5.9 μM. Datelliptium also leads to a concentration-dependent decrease in gluconeogenesis from lactate in cells[1]. Datelliptium acetate is selectively cytotoxic for solid tumors over leukemia L1210. Human tumors H-125 and HCT-116 demonstrates less sensitivity to datelliptium acetate[2].
Upon intravenous administration, datelliptium acetate shows potent inhibitory activities in vivo against a variety of murine solid tumors. Datelliptium acetate is highly active against early-stage colon #38 with highest non-toxic dose (HNTD) of 170 mg/kg TD, and weight loss of 10%, T/C of 0%[2].


Catalog Number M007298
CAS Number 105118-14-7
Synonyms

2-[2-(diethylamino)ethyl]-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-2-ium-9-ol;chloride

Molecular Formula C23H28ClN3O
Purity ≥95%
InChI InChI=1S/C23H27N3O.ClH/c1-5-25(6-2)11-12-26-10-9-18-16(4)23-22(15(3)20(18)14-26)19-13-17(27)7-8-21(19)24-23;/h7-10,13-14,27H,5-6,11-12H2,1-4H3;1H
InChIKey UCICRVXYPSKKJK-UHFFFAOYSA-N
SMILES CCN(CC)CC[N+]1=CC2=C(C3=C(C(=C2C=C1)C)NC4=C3C=C(C=C4)O)C.[Cl-]
Reference

[1]. Donato MT, et al. Toxicity of the antitumoral drug datelliptium in hepatic cells: Use of models in vitro for the prediction of toxicity in vivo. Toxicol In Vitro. 1992 Jul;6(4):295-302.
 [Content Brief]

[2]. Mucci-LoRusso P, et al. Activity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice. Invest New Drugs. 1990 Aug;8(3):253-61.
 [Content Brief]

Request a Quote